The company's financial results
MiNK Therapeutics (NASDAQ: INKT) today released its financial results for Q4th and full year 2021.
MiNK's shares opened at US$2.69 in yesterday's trading and closed at US$3.10 (+19.69%).
The company's Volume was 136,807 and Avg. Volume is 80,681. Also, over the last five days, the company's shares have added 16.54% and the highest value per share was US$3.10 and the lowest value was US$2.17.
The company's market capitalisation to date stands at US$103.864 million.
The company has a 52-week high of US$22.16 and a 52-week low of US$2.16.
Report from biopharmaceutical company
The company reported a cash balance of 39 million US dollars as of 31 December 2021.
Also, the company reported a net loss of US$30 million for the year. However, the net loss for Q4th is US$6 million.
The IPO was completed with proceeds of 46 million USD and the annual cash outflow for 2021 is about 13 million USD.
It is worth noting that the company has also reported that clinical trials of AgenT-797 (Allo-iNKTs) anti-PD-1 in solid tumours are underway.
MiNK Therapeutics was founded in 2017 and the company is a subsidiary of Agenus.
Also, Garo Armen is Chairman of the company, John Baldoni, Peter Behner, Brian Corvese, Barbara Ryan and Ulf Wiinberg are Directors, Jennifer Buell is President and CEO of the MiNK.
